Elaprase®

Understanding Elaprase® 

Elaprase® (idursulfase) is an enzyme replacement therapy (ERT) used to treat Hunter syndrome (Mucopolysaccharidosis type II, MPS II), a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. This deficiency leads to the accumulation of glycosaminoglycans (GAGs) in the body’s cells, causing progressive organ damage and functional impairments.

How Elaprase® Works:

• Replaces the deficient iduronate-2-sulfatase enzyme to prevent GAG accumulation
• Improves lung function and mobility, reducing disease complications
• Slows disease progression, leading to better long-term outcomes

FDA Approval:

• Elaprase® (idursulfase): Approved in 2006

For more information, please visit the Elaprase® patient website and speak with your healthcare provider to determine if Elaprase® is the right treatment option for you.